Anrok

Helps the daring build legendary companies, from idea to IPO and beyond.

Fund based in London, San Francisco and Geneva, helping entrepreneurs turn bold ideas into transformative international businesses. Index covers every investment stage, from earliest seed through to explosive growth.

Broadly, a venture we back offers one or more of the factors: 1. Significant technology or business model innovation 2. “Black Swan” ideas with significant upside or a significantly better mousetrap 3. Large markets, either existing or newly enabled by the innovation at hand 4. Short innovation cycles 5. Upfront risk

Elad Gil is an active angel investor and was the co-founder of Color Genomics and former vice president of Twitter.

I look for audacious authenticity. The audacious part is that it has to be a big idea that will truly make a difference in the world. But to me, authenticity is most important. Someone who understands a problem space better than anyone else will be the absolute best steward for their company. They’re never going to give up on their idea, and no one can compete with their instincts and commitment. My goal is to be a founder’s first call. That’s not something you can add to a term sheet. It has to be earned—through trust, delivery and being there when things are messy and hard. Real company-building is not glamorous work. I thrive on partnering with people who will make a dent in tomorrow—and on being there with whatever they need to maximize that dent.

I strongly believe in immigrant founders: I saw firsthand the sheer tenacity of my parents who built a business while raising two daughters in a country where everything was foreign to them. I viscerally appreciate the challenges and the hopes of those chasing the American Dream—for many immigrants, there is more at stake than just their company. I nearly drowned as a child. I sobbed all day, and the day after that, I asked to enroll in swimming lessons. There are moments where every founder feels like they’re drowning—I want to be their first call when that happens. I started doing research in immunology when I was in middle school. I did translational oncology at Genentech, and then studied a new protein target to slow Alzheimer’s in college. At Stanford, I was able to marry my interests in biology with statistics and computer science, and I am excited to meet entrepreneurs innovating at that intersection.

Cristina previously served as the Head of Platform & Partnerships at Notion. Before Notion, Cristina spent more than seven years at Stripe as it scaled from 28 to nearly 3000 people, leading the Partnerships function and the business units for Stripe’s Corporate Card & Treasury products.Cristina was also previously an active angel investor, focusing on founders building fintech, SaaS and developer products as she advised and invested in more than 50 startups.